Skip banner and top navigation
NHLBI Logo and Link
National Heart, Lung, and Blood Institute: People, Science, Health
TechFinder Public Technology Searches
Link to the National Institutes of Health Link to the Department of Health and Human Services

Tech Transfer HomeTechFinder HomeTechFinder SearchMy Account

 Technology Information 
Treatment of Cardiovascular Conditions with Nitrite
00/00/00
Unlicensed
Description of Invention:
Different therapeutic classes of compounds that are able to increase blood flow and act as vasodilators have been used to treat a wide variety of disease indications including cardiovascular and respiratory diseases. Endothelium-derived factors, such as nitric oxide (NO), play a crucial role in the maintenance of vascular homeostasis and NO-enhancing compounds have been administered alone or in combination with an approved pharmaceutical agent in order to provide an effective therapeutic treatment. Many of these therapies are very costly and there remains a strong need for an affordable treatment. Recent scientific work by the inventors provided evidence that the anion nitrite represents a circulating and tissue storage form of nitric oxide whose bioactivation is mediated by the nitrite reductase activity of deoxyhemoglobin [Nature Medicine 2003 9(12):1498-1505].

NIH scientists and their collaborators have now shown that low, physiological and non-toxic concentrations of sodium nitrite are able to increase blood flow and produce vasodilation by infused and nebulised routes of administration. Proof of concept data has been obtained in animal models for myocardial and hepatic ischemia and reperfusion injury, in a neonate lamb model for neonatal pulmonary hypertension, and in a primate model for prevention of delayed cerebral vasospasm following sub-arachnoid hemorrhage. The implications of these results point to the use of nitrite as a potential cost-effective platform therapy for a wide variety of disease indications characterized broadly by constricted blood flow or tissue hypoxia. Available for licensing are method of use claims for nitrite salt formulations directed to conditions associated with high blood pressure, decreased blood flow or hemolytic disease (E-254-2003/2) and for the treatment of specific conditions such as pulmonary hypertension, cerebral artery vasospasm and hepatic, cardiac or brain ischemia-reperfusion injury (E-254-2003/3).


Inventors:
M. Gladwin (CC),
R. Cannon (NHLBI),
A. Schechter (NIDDK),
C. Hunter (CC),
R. Pluta (NINDS),
E. Oldfield (NINDS),
D. Kim-Shapiro (EM),
R. Patel (EM),
D. Lefer (EM),
G. Power (EM).

Patent Status:
DHHS Reference No. E-254-2003/0-US-01 filed 09 Jul 2003 (U.S. Patent Application 60/484,959);
DHHS Reference No. E-254-2003/1-US-01 filed 14 Oct 2003 (U.S. Patent Application 60/511,244);
DHHS Reference Nos. E-254-2003/2-PCT-01 and E-254-2003/3-PCT-01 filed 09 Jul 2004 (PCT Applications) .

Portfolios:
Central Nervous System -Therapeutics-Neurological Therapeutics-Stroke-Internal Medicine-Therapeutics-Cardiology-Vasodilators.





For Additional Information Please Contact:
Susan Carson D.Phil.,
Office of Technology Transfer,
6011 Executive Blvd, Suite 325,
Rockville, MD 20852-3804,
Phone: (301) 435-5020,
Email: carsonsu@mail.nih.gov,
Fax: (301) 402-0220.


Nitrite, vasodilator, NO, Human Circulation
 Links Listing 
Name Description Opens a New Browser Window
Publication Link Relevant Publication More Information
Please Note: Clicking on the More Information link will open a new browser window.

Request Information
If you are a registered user, please login before requesting information by clicking the Login button. If you have not registered, click the Login button for registration information.
Skip footer links and go to content

OFFICE OF TECHNOLOGY TRANSFER HOME · ACCESSIBILITY · PRIVACY STATEMENT · FOIA · CONTACT US